

# The LINC01260 Functions as a Tumor Suppressor via the miR-562/CYLD/NF-κB Pathway in Non-Small Cell Lung Cancer [Retraction]

Chen Y, Lei Y, Lin J, et al. *Onco Targets Ther.* 2020;13:10707-10719.

At the author's request, we, the Editors and Publisher of *OncoTargets and Therapy* have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figures 2, 4 and 7 with images from other unrelated articles. Specifically,

- Images for Figure 2D have been duplicated with images for Figure 2F from Luo J, Jin Y, Li M, Dong L. Tumor suppressor miR-613 induces cisplatin sensitivity in non-small cell lung cancer cells by targeting GJA1. *Molecular Medicine Reports.* 2021;23:385. <https://doi.org/10.3892/mmr.2021.12024>.
- The images for Figure 4A, sh-LINC01260 and sh-Control have been duplicated with the images for Figure 3A, NC and miR-613 mimics, respectively, from Luo et al, 2021.
- Images for Figure 4F have been duplicated with images for Figure 1D from Xu L, Zhang B, Li W. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2. *Molecular Medicine Reports.* 2021;23:263. <https://doi.org/10.3892/mmr.2021.11902>; Figure 3F from Zhang X, Lian T, Fan W, et al. Long-Noncoding RNA CASC9 Promotes Progression of Non-Small Cell Lung Cancer by Promoting the Expression of CDC6 Through Binding to HuR. *Cancer Manag Res.* 2020;12:9033-9043. <https://doi.org/10.2147/CMAR.S268375>; Figure 7d from Qu Z, Li S. Long noncoding RNA LINC01278 favors the progression of osteosarcoma via modulating miR-133a-3p/PTHR1 signaling. *J Cell Physiol.* 2020;1–13. <https://doi.org/10.1002/jcp.29582> and Figure 7F from Zhang RL, Aimudula A, Dai JH, Bao YX. RASA1 inhibits the progression of renal cell carcinoma by decreasing the expression of miR-223-3p and promoting the expression of FBXW7. *Biosci Rep.* 2020;40(7):BSR20194143. doi: <https://doi.org/10.1042/BSR20194143>.
- The image for Figure 4G, PCNA, sh-LINC01260 has been duplicated with the image 3E, Ki-67, NC from Luo et al, 2021.
- Images for Figure 7F have been duplicated with images for Figure 1e from Liu S, Liu LH, Hu WW, Wang M. Long noncoding RNA TUG1 regulates the development of oral squamous cell carcinoma through sponging miR-524-5p to mediate DLX1 expression as a competitive endogenous RNA. *J Cell Physiol.* 2019;234:20206–20216. <https://doi.org/10.1002/jcp.28620> and Figure 2D and 2H from Xing T, Chen P, Wu J, et al. UPF1 Participates in the Progression of Endometrial Cancer by Inhibiting the Expression of lncRNA PVT1. *Onco Targets Ther.* 2020;13:2103-2114. <https://doi.org/10.2147/OTT.S233149>.

The authors explained that a third party had carried out the experiments and there had been an equipment malfunction. However, it was not made clear how this subsequently led to the duplication of several images across multiple, unrelated articles. In addition, the authors were unable to provide original data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the authors requested to retract the article and the Editor and Publisher agreed with this decision.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'.

**OncoTargets and Therapy****Dovepress****Publish your work in this journal**

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

<https://doi.org/10.2147/OTT.S455821>